Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
AquaBeam is a minimally invasive medical device that allows rapid removal of prostate tissue without leaving a zone of thermal damage on the treated tissue. The AquaBeam device combines image guidance and robotics with a high pressure saline jet for targeted and heat-free removal of prostate tissue. It is intended for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
The KineSpring System and next-generation Atlas Knee System are medial compartment joint unloading implants that work like shock absorbers. Both implants may be removed if necessary without interfering with future surgical options for worsening osteoarthritis (OA). They are designed to absorb approximately 30 pounds of joint load, and are intended for patients with mild-to-moderate medial knee OA that is painful, debilitating, and refractory to standard conservative treatments. Candidates for these implants are typically middle-aged and want to prolong the time before a total knee arthroplasty is imperative.
OPN-375 is an investigational drug-device product for the treatment of nasal polyposis in adults. The product combines a novel, closed palate, bidirectional drug delivery platform with fluticasone propionate, which is a topical steroid. The drug delivery device is powered by the user’s own breath. It has both a mouthpiece and a sealing nosepiece designed to expand the upper part of the nasal valve. The user exhales into the mouthpiece, closing their soft palate and isolating the nasal cavity from their mouth and lungs. The exhaled breath propels the medication through the nosepiece and beyond the nasal valve deep into the...
RBX2660 is a microbiota-based investigational product for fecal microbiota transplantation proposed to treat recurrent Clostridium difficile infection. It is derived from fresh stool from multiple donors; both donors and stool samples are methodically screened. Pooled stool samples are commercially prepared under good manufacturing processes. RBX2660 is packaged in ready-to-use enemas.
Tecentriq is an intravenous humanized monoclonal antibody that targets PD-L1, an immune checkpoint protein expressed on certain tumor cells (TC) and tumor-infiltrating immune cells (IC). It inhibits interaction between PD-L1 and PD-1. Tecentriq is FDA-approved for second-line treatment of locally advanced or metastatic non-small cell lung cancer. Tecentriq is also approved to treate urothelial carcinoma.